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The Imaginary Worlds of ISPOR:  Modeled Cost-Effectiveness Claims Published in Value 
in Health from January 2016 to December 2016 
Paul C Langley, PhD and Taeho Greg Rhee, PhD  
College of Pharmacy, University of Minnesota 
 
Abstract  
In 2016, a review of modeled cost-effectiveness studies published in Value in Health between January 2015 and December 2015 was 
presented. The purpose of the review was to consider whether these modeled claims for cost-effectiveness met the standards of normal 
science: were the claims made credible, evaluable and replicable? The review concluded that none of the 16 studies assessed met this 
standard. They should be seen as thought experiments; the construction of imaginary worlds which should be categorized as 
pseudoscience. The reader, or health care decision maker, would have had no idea, and would never know, whether the claims were 
right, wrong or misleading. Similar reviews were undertaken in Pharmacoeconomics and the Journal of Medical Economics and came 
to the same conclusion. The purpose of this second review is to consider the modeled claims published in Value in Health between 
January 2016 and December 2016, applying the same criteria. Unfortunately, for those who subscribe to the standards of normal 
science, we must come to the same conclusion. Of the 13 economic evaluations reviewed, 12 simulated claims that were immune to 
failure. The model structures ensured that the claims were neither evaluable nor replicable. They were categorized as pseudoscience; 
they failed to meet the standards of normal science. Five of these studies were supported by manufacturers and all supported the 
manufacturer’s product. Three systematic reviews were also evaluated. Once again, there was a failure to consider meeting the 
standards of normal science in presenting modeled claims for cost-effectiveness. 
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Introduction 
In mid-2016, a commentary was published in INNOVATIONS in 
Pharmacy reviewing, from the perspective of the standards of 
normal science, modeled technology assessment claims 
published in Value in Health from January 2015 to December 
20151. This systematic review concluded that of the 16 
identified papers, 14 presented a cost-per-QALY  analysis, with 
9 presenting their claims in a lifetime cost-per-QALY 
framework. The technology assessments presented, while 
conforming to ISPOR recommended standards, failed to meet 
the standards of normal science: the claims were neither 
credible, nor were they evaluable and replicable. They were 
best seen as imaginary claims created by imaginary modeled 
worlds. Recipients of these claims had no idea whether they 
were right or whether they were wrong, and they would never 
know as the claims were immune to failure. Reviews of 
modeled studies published in Pharmacoeconomics and the 
Journal of Medical Economics over the same time period came 
to the same conclusion 2 3. 
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These reviews of cost-effectiveness models are part of a series 
of commentaries published in INNOVATIONS in Pharmacy over 
the last 12 months that have focused on the evidentiary 
standards for claims assessment. These standards are  
required or recommended by technology assessment agencies 
such as the National Institute for Health and Care Excellence 
(NICE) in the UK and the Pharmaceutical Benefits Advisory 
Committee (PBAC) in Australia, professional groups such as the 
International Society for Pharmacoeconomics and Outcomes 
research (ISPOR) and the Academy of Managed Care Pharmacy 
(AMCP) in the US and independent research groups such as the 
Institute for Clinical and Economic Review (ICER) 4 5 6 7 8 9 10. 
The common theme in these commentaries has been that the 
standards proposed and accepted in health technology 
assessment in the construction of non-evaluable modeled 
claims for pharmaceutical products and devices should be seen 
as pseudoscience (a.k.a. pure bunk); as intelligent design 
rather than natural selection 11 12 
 
In case this characterization might appear as an unnecessarily 
harsh judgement on standards that have been in place for 30 
years or more and which have been applied in literally 
thousands of published, peer review studies and evaluations 
by technology assessment groups, the commentaries recently 
pointed to the latest version of the guidelines released in 
March 2017 by the Canadian Agency for Drugs and 
Technologies in Health (CADTH). The CADTH guidelines made 
it quite clear that their technology assessment framework is 
not to be judged by the standards of normal science 13. The 
guidelines are designed to set criteria for the construction of 
imaginary simulations to support cost-outcomes claims, to 
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‘inform’ health system decision makers, not to test 
hypotheses. Supporting claims that are credible, evaluable and 
replicable are put to one side by CADTH in favor of the 
construction of imaginary worlds. Typically an imaginary 
simulation of benefits and harms, focused on health related 
quality of life (HRQoL) over the lifetime of a hypothetical target 
population. 
 
The purpose of this second review of health technology 
assessment studies published in Value in Health is to consider 
whether the standards of normal science continue to be put to 
one side, with the Journal continuing to accept simulated non-
evaluable claims generated by imaginary worlds. The period 
covers January 2016 to December 2016. It will be followed by 
reviews over the same time period for Pharmacoeconomics 
and the Journal of Medical Economics.  
 
Methods 
A systematic review, following the PRISMA-P checklist (MeSH 
terms ‘cost’, ‘cost effectiveness’, ‘Markov’, ‘QALY’) of all 
papers published in Value in Health in  2016 was undertaken 
14. In order to judge whether the modeled claims presented 
met the standards of normal science four questions were 
considered: 
• Is the model capable of generating testable claims? 
• Did the author(s) attempt to generate testable 
claims? 
• Did the authors suggest how the claims might be 
evaluated? 
• Did the author(s) caution readers as to the 
implications of generating non-testable claims? 
Each author independently reviewed the selected studies with 
consensus agreement reached on the assessment. 
 
A testable claim was defined as one that could be evaluated 
empirically in a timeframe relevant to the needs of a formulary 
committee (ideally a period of 2 to 3 years). This period was 
chosen because a testable claim was seen as provisional. A 
product or device could, in this context, be accepted by a 
formulary committee for formulary listing, but subject to an 
agreement with the manufacturer to report back to the 
committee with evidence to support the claims made. These 
claims could be for anticipated product comparative 
effectiveness, for the impact of the product on resource 
utilization or some combination of these to support a claim for 
incremental cost-effectiveness. The claim for comparative 
effectiveness could encompass clinical endpoints as well as 
those captured as patient reported outcomes (PROs) such as 
health related quality of life (HRQoL) and quality adjusted life 
years (QALYs). 
In judging whether or not a model might support testable 
(falsifiable) claims, even if the possibility was not considered 
by the authors(s), three characteristics of the model are 
important. These are (i) the modeling framework, (ii) the 
choice of primary outcome measure; and (iii) the time frame 
for the model.  A Markov or discreet event simulation model 
with a lifetime perspective and with discounted cost per QALY 
claims as the primary endpoints would be one where 
comparative claims would be impossible to evaluate. There is 
no chance of falsification, feedback to decision makers or 
replication.  It would be assessed as immune to failure. Against 
this, a simple, trial-based decision model with a timeframe of 
12 to 18 months with claims expressed in clinical, PRO and 
resource utilization endpoints would be open to hypothesis 
testing and feedback to a formulary committee. Even with a 
short-term time horizon, however, the choice of outcome may 
not be evaluable outside of a protocol-driven observational 
study.  If health care systems do not collect specific QALY 
measures on an ongoing basis then it is impossible to evaluate 
cost-per-QALY willingness-to-pay threshold claims from 
integrated data bases. This assumes, of course, that the QALY 
measure that might be collected is consistent with the 
measure utilized in the simulation model.  
 
Apart from evaluating the published economic evaluations, 
attention was also given to systematic reviews published in 
Value in Health. Two questions are relevant: 
• Did the systematic review of economic evaluations 
address the issue of the credibility, evaluation and 
replication of clinical claims in the respective 
modeled economic evaluations; and 
• Did the systematic review recommend (or caution 
against) accepting the claims from the modeled 
economic evaluations as the basis for formulary 
decisions 
Results 
A total of 13 papers classified by Value in Health as either 
economic evaluations or comparative effectiveness research 
were identified (Table 1). As well, three systematic reviews 
were identified as these were directly related to the issues 
raised in this review (Table 2).   
 
Modeled Cost-Effectiveness Claims 
Key findings are: 
• Only one of the studies provided comparative claims 
that met the standards of normal science16 
• None of the claims presented in other 12 papers 
were credible, evaluable and replicable 
• Modeled time horizons for the claims presented in 
these 12 papers ensured the claims were immune to 
failure  
• Five of these economic evaluations were funded 
directly by pharmaceutical manufacturers and all 
simulated claims that supported the manufacturer’s 
product 17 18 20  24 25 
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• Two more of the economic evaluations had 
manufacturer links and both supported the 
manufacturer’s product 19 27 
• None of the papers considered how the claims might 
be evaluated in treatment practice 
Modeled Claims and Systematic Reviews 
In terms of the questions raised, none of the reviews 
addressed the issue of the credibility, evaluation and 
replication of modeled claims neither did they explicitly 
recommend or caution against accepting the modeled claims 
as the basis for formulary submissions. The only qualification 
here is from the Brilleman et al study which, in addressing 
claims for cost-effectiveness modeled on clinical trials, points 
to the lack of standards potentially impacting model-based 
claims for cost-effectiveness and the need for reporting on 
cost-allocation 28. A key point to note in the Brilleman et al 
study is that: ‘None of the articles included in our review used 
statistical methods to adjust for non-adherence or incorporate 
non-adherence information directly into the economic 
evaluation’ (p. 103). 
 
Discussion 
As noted above, the common theme in the commentaries 
published in INNOVATIONS in Pharmacy since mid-2016 is that 
the recommended standards and their application in health 
technology assessments fail to meet the standards of normal 
science 4. Rather than focusing on generating testable 
hypotheses to assess anticipated comparative product 
performance, the studies fall back on creating modeled 
imaginary worlds in which the comparative claims are immune 
to failure. The exemplars here are the lifetime cost-per-QALY 
willingness-to-pay ‘reference case’ model structures, which 
support ‘information only’ formulary submissions where the 
claims are non-evaluable 6. This review of economic 
evaluations in Value in Health for calendar 2016 demonstrates 
that, despite criticisms raised against the construction of 
simulated imaginary worlds and their characterization as 
‘pseudoscience’, this acceptance of imaginary constructs 
continues. 
 
Consider the question, for example, of cost-per-QALY 
estimates and willingness-to-pay thresholds. Imaginary model 
simulations that yield lifetime claims that propose that  market 
entry prices of a product are not cost-effective are, as noted in 
reviews of ICER evidence reports, immune to failure 8 9 10. As 
such they fail the standards of normal science and should be 
rejected. 
 
Modeled Claims 
Once a study design commits to a long-term or lifetime Markov 
(or similar) model, there is no chance that the evaluation will 
generate claims that are credible and evaluable. Irrespective 
of the technical appeal in constructing multi-health state 
treatment pathway models that may extend for decades into 
an unknown future, with assumptions justified to appeals to 
literature or short term RCTs, the reader has to take the claims 
at face value. The Gregory et al paper, to give one example, 
projects on a yearly cycle from age 10 years to death or 100 
years in the risks from computed tomography in Ireland 15  
Other models in Value in Health have lifetime horizons, 
horizons of 25 years and horizons of 20 years. 
 
Certainly, if we are prepared to suspend our disbelief in these 
constructs, we could point to a number of ways in which the 
‘realism’ of the imaginary world could be enhanced. These 
have been detailed in previous commentaries and could 
include assumptions capturing anticipated patterns of 
persistence and adherence, presence and impact of 
comorbidities, anticipated pricing policies for annualized 
whole sale acquisition cost (WAC) price increases, possible 
WAC discounting to target patient groups, entry of pipeline 
competitor products and assumptions as to unknown but 
possibly defensible therapy switching patterns following initial 
response. Unfortunately, ‘improving’ the appeal of an 
imaginary construct merely increases the number of 
competing scenarios. Rather than providing ‘more 
information’ to support decision making, the more likely result 
is information overload and the rejection of the model. 
Consider, for example the issues of adherence and 
persistence. These are typically overlooked (or ignored) in 
constructing lifetime models. This is an odd decision given that 
there is now ample evidence for limited persistence with the 
majority of patients in disease areas abandoning a therapy 
within two to three years of an index prescription. If claims for 
persistence (let alone adherence) are based upon RCTs then as 
Brilleman et al point out, the evidence base may be somewhat 
questionable 28. 
 
The belief in the credibility of modeled claims may be further 
tested by manufacturer sponsored models, which readers 
might regard as ‘marketing exercises’. In this review, five of the 
economic evaluations were sponsored or funded by 
manufacturers. As noted, all of these supported non-evaluable 
claims for the manufacturer’s product. The absence of an 
evaluable claims means that there is no basis for assessing the 
‘validity’ of the model claims. Competing models sponsored by 
manufacturers in the same class of comparator products 
might, not surprisingly, come to quite different conclusions. If 
journals such as Value in Health are prepared to publish 
manufacturer support models the, at least, there could be a 
‘red flag’ annotation with the peer review process assessing 
(and reporting) on the model presented in the context of other 
models in the therapy area. EEven so,  we will still have 
competing claims where the authors of the systematic review 
will attempt to explain that variation in terms of model 
structures, assumptions and presumptions of willingness-to-
pay; an exercise which is pointless in the absence of modeled 
credible and evaluable claims with possible feedback from 
target populations.  
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Systematic Reviews 
Even if the authors of imaginary worlds claim to be adherent 
to a ‘reference case’ mandated by a technology assessment 
group, there is ample opportunity to propose alternative 
model structures and input assumptions to make the case for 
comparative efficacy or effectiveness. It might be argued that 
subjecting a submitted model to the ministrations of an 
evidence review group would resolve this issue. Unfortunately, 
it does not solve the problem. Blinded assessments by 
competing review groups could come to quite different 
conclusions as to the ‘preferred’ model structure and the 
‘appropriate’ input assumptions.  
 
The Kirsch review of Markov modeling in disease management 
programs, following the ISPOR good practice guidelines for 
decision-analytic modeling, reviewed 16 studies 30. In chronic 
heart disease the results ranged from cost savings of $657 and 
an increase of 0.0051 QALYs to an increase in costs of $4,607 
per life year gained (LYG) and $146,544 per QALY. The two 
asthma studies also yielded cost savings or additional costs, 
with the five diabetes studies reported again both cost savings 
and additional costs. A detailed comparison of the various 
models was  presented pointing to varying quality (‘far from 
perfect’)  and coverage in terms of, for example, model 
structure, model cycle length, time horizon, utility weights, 
costs and parameter sensitivity. The author found it difficult to 
determine whether funders tried to influence study results or 
prevent the publication of unfavorable results.  
 
Kirsch concluded that if the problems identified in the review 
are addressed then ‘Markov models should be more suitable 
to evaluate economic effects of multicomponent 
interventions, and provide helpful information for decision 
makers’ (p. 1052) 30. Apart from the question of what is 
considered ‘helpful’ as opposed to possibly misleading 
information, this conclusion misses the point. At no stage in 
the review is the issue of establishing credible, evaluable and 
replicable claims for disease management programs 
considered. Even if model builders ‘improved’ the quality of 
the Markov model decision makers would be no further ahead. 
They would still be faced with imaginary claims and the 
possibility of an endless procession of diverse claims.  We are 
still in the CADTH-mandated realm of pseudoscience, hoping 
that our non-evaluable claims will ‘inform’ decision makers.  
 
The same objections apply to the Nunes et al review of long-
term mechanical circulatory support 29. Following a literature 
search a total of 11 country-specific cost-effectiveness 
analyses were identified. Once again the object is seen to be 
to ‘inform’ decision makers ‘such that societal benefit is 
maximized’. The focus is on non-evaluable ICER thresholds 
rather than on presenting claims for devices that are credible, 
evaluable and replicable. The non-evaluable modeled results, 
not unexpectedly, vary widely. In mechanical circulatory 
support as a bridge to transplantation. ICERs between this 
support and medical management ranged from C$85,025 and 
C$200,166  per QALY and for destination between C$87,622 
and C$1,257,946 per QALY. The authors concluded that the 
adoption of mechanical circulatory support has occurred 
despite, apparently, not achieving stated or implied cost-
effectiveness thresholds. Indeed, no study in the review 
‘concluded that mechanical circulatory support is cost-
effective with respect to optimal medical management’. While 
an assessment of possible contributing factors is apparently 
outside the scope of the review, one possible reason is that 
decision makers are not interested in being merely ‘informed’ 
through imaginary ICER models, presenting with such diverse 
claims, but are looking to evaluable claims and feedback from 
those claims to support purchasing decisions.  
 
A major criticism of modeled claims for cost-effectiveness is 
that the models typically ignore issues of adherence and 
persistence with therapy. In previous commentaries it has 
been pointed out that if patients are non-persistent with 
therapy then if the majority of patients are non-compliance 
within two to three years of an index prescription 4. It makes 
little sense to advocate formulary acceptance from a lifetime 
high-compliance cost-utility model. The importance of the 
Brilleman et al review is to emphasize how poorly adherence 
and persistence behavior are captured in clinical trial protocols 
and the importance of this for economic evaluations alongside 
clinical trials 28. To which might be added the implications of 
taking trial end points as inputs to the creation of modeled 
imaginary worlds when these are potentially impacted by 
compliance behavior.  
 
Conclusions 
In a recent commentary on the ICER evidence review for PCSK9 
inhibitors, the question was raised as to the likelihood that 
authors of health technology assessments could put what can 
be seen as the pointless construction of evidence and 
comparative claims from imaginary worlds behind them 10. 
Committing themselves instead to a research program for 
comparative claims assessment that embraced the standards 
of normal science and not its explicit rejection as evidenced by 
the latest CADTH guidelines 13. In support of this, it was also 
proposed that journal editors could make it clear to their 
readership that published modeled claims, if they persisted in 
focusing on non-evaluable claims, could caution that the 
results presented did not meet the standards of normal 
science. A ‘red flag’ warning that would clarify circumstances 
where the modeled claims could be interpreted as a marketing 
exercise.  
 
The PCSK9 commentary concluded that this ‘reformation’ was 
unlikely to occur 10. There were too many vested interests in 
supporting the status quo. After all, with over 30 years 
acceptance and publication of literally thousands of non-
evaluable claims in the leading journals, and acceptance of this 
commitment to constructed evidence by agencies such as 
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NICE, CADTH and the PBAC, the discomfiture would be (to say 
the least) embarrassing. Let alone, it should be added, the 
impact on thousands of graduate students and others who 
have been trained to construct imaginary worlds and put the 
standards of normal science to one side. Richard Dawkins, in 
Unweaving the Rainbow, recognizes our willingness to feed on 
‘superstition, the paranormal and astrology’ 31.  Or, as he 
describes it, our continuing appetite for being ‘Hoodwink’d 
with faery fancy’ . Perhaps we could recognize our appetite for 
‘faery fancy’ and put the endorsement and publication of 
modeled imaginary worlds behind us. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Imaginary Worlds: Modeled Economic Evaluation Studies in Value In Health January 2016 to December 2016 
 
Paper 
(author) 
Target 
Population and 
Intervention 
Sponsor (if 
any) 
Modeling Technique and Claims Status Claims Assessment 
and Credibility 
Gregory et al 
15 
Protocol for 
diagnosis of 
appendicitis in 
children 
None 
stated 
Study objective to apply a decision model to 
quantify the benefits, costs and harms for 
children with suspected appendicitis 
considering a validated clinical decision rule 
and a staged ultrasound and computed 
tomography imaging protocol. Markov model 
applied to estimate long-term clinical and 
economic outcomes. In absence of empirical 
data the Markov model was used to estimate 
radiation-induced cancer risks resulting from 
computed tomography. Simulation of 100,000 
hypothetical population on a yearly cycle from 
age 10 years to death or 100 years. Strategies 
compared on basis of estimated health 
benefits and QALYs. With a discount rate of 3% 
cost-effectiveness assessed against 
willingness-to-pay thresholds of $50,000 and 
$100,000.  QALY gains minimal; for both boys 
and girls willingness-to-pay thresholds 
exceeded.   
No consideration of 
modeled credible, 
evaluable and 
replicable claims. No 
possibility of meeting 
standards of normal 
science given Markov 
framework and 
timelines.  
Johnson et 
al16 
Increasing 
physical activity 
and 
maintaining 
weight in 
sedentary 
African 
American 
Women 
National 
Institute 
for Nursing 
Research 
To evaluate the 48-week Women’s Lifestyle 
Physical Activity Program trial. Outcomes 
reported included physical outcomes, weight 
stability and marginal cost effectiveness ratios 
for each outcome with bootstrap confidence 
intervals. 
Absence of  
consideration of 
possible protocol(s) to 
evaluate the 
introduction of this 
program in treatment 
practice and 
cost/physical activity 
outcomes criteria for 
continuing support. 
Tilden et al 17 Management of 
blepharospasm 
Merz 
Pharmaceu
ticals 
Markov state transition model to support a 
cost-utility analysis comparing 
incobotulinumtoxin-A (the sponsor’s product) 
No consideration of 
modeled credible, 
evaluable and 
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and cervical 
dystonia 
to onabotulinumtoxin –A (Allergan) in an 
Australian modeled environment. Three health 
states modeled and patients followed on 
weekly cycles up to 5-years. HRQoL assessed 
via EQ-5D instrument. Results supported 
incobotulinumtoxin-A with with incremental 
cost per QALY of A425,588 and A423794 
respectively in blepharospasm and cervical 
dystonia. QALYs gained for 
incobotulinumtoxin-A due to earlier alleviation 
of symptoms in model.  
replicable claims. No 
recommendation for 
meeting required 
standards of normal 
science in protocol-
driven claims 
assessment outside of 
model. 
Heijnsdijk  et 
al 18 
Prostate cancer 
detection with 
Prostate Health 
Index 
Beckman 
Coulter Inc 
Modeled assessment of Beckman Coulter 
Prostate Health Index (PHI - the sponsor’s 
product) based on European Randomized 
Study of Screening for Prostate Cancer Trial. 
Object to evaluate effects of prostate-specific 
antigen (PSA) screening with PHI vs. PSA-only. 
Model predicted number of prostate cancers, 
negative biopsies, deaths, QALYs of PSA and 
PHI in a hypothetical population aged 50 to 75 
years tested at 4-year intervals. Conclusion: 
compared to PSA, PHI reduced number of 
negative biopsies and more cost-effective. 
Although authors 
suggest additional 
research, no 
consideration of 
modeled credible, 
evaluable and 
replicable claims. No 
recommendation for 
protocols to support 
claims assessment and 
meeting required 
standards of normal 
science. 
Becker et al 
19 
Options in 
patients with 
previously 
untreated 
chronic 
lymphocytic 
leukemia 
Support for 
third party 
writing 
assistance 
from F 
Hoffmann-
La Roche 
Ltd 
Markov model with a base-case time horizon 
of 20 years (considered equivalent to lifetime). 
Assessed the cost-effectiveness of six 
alternative first-line treatments, to include 
anti-CD20 monoclonoal antibody 
obinutuzumab plus chlorambucil (GClb – 
Hoffman La Roche) in untreated patients with 
chronic lymphocytic leukemia unsuited for full-
dose fludarabine therapy from a UK NHS 
perspective. Three health states: progression 
free survival, progression and death. In base-
case GClb cost-effective against all 
comparators in the model under a range of 
plausible modeled scenarios. 
Claims presented are 
non-evaluable No 
recommendation for  
protocols to support 
claims assessment to 
meet required 
standards of normal 
science. 
Bijlani et al20  Prostate 
surgery costs 
with robotic-
assisted versus 
retropubic 
radical 
prostatectomy 
Intuitive 
Surgical 
Modeled care pathway analysis, including 
multiple iterations with pathways, from 
hospital and payer perspectives comparing 
robotioc assisted laparoscopic prostatectomy 
(RALP – the sponsor’s product) versus 
retropubic radical prostatectomy (RRP). 
Clinical outcomes modeled from systematic 
literature review. Monte-Carlo probabilistic 
sensitivity analysis generated claim that RALP 
had a 38% to 99% probability of cost-savings. 
Claims presented are 
non-evaluable No 
recommendation for  
protocols to support 
claims assessment to 
meet required 
standards of normal 
science. 
Rafia et al21 Alternative 
upper age limits 
for breast 
cancer 
screening 
UK 
National 
Institute 
for Health 
Grant 
To assess whether the extension of breast 
screening to women older than 70 years would 
be cost-effective from a UK NHS perspective. A 
natural history model breast cancer 
progression model simulated time at which 
breast cancer presents and its characteristics 
Claims presented are 
non-evaluable No 
recommendation for  
protocols to support 
claims assessment to 
meet required 
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at time of detection in absence of screening vs. 
characteristics of cancer if detected earlier 
through screening. Six health states identified  
with utilities determined by expert opinion. 
Outcomes were modeled number of cases 
detected/ 105 screened, incremental 
discounted life years and quality of life years/ 
105 screened, incremental discounted costs / 
105 screened, discounted costs per life years 
gained and QALYs gained.  
standards of normal 
science. 
Hinde S et 
al22  
Advanced 
ovarian cancer 
Funded as 
part of 
ICON7, a 
UK Medical 
Research 
Council 
sponsored, 
academic-
led and 
Roche 
supported 
trial.  
A partitioned lifetime survival model with 
three disease states (preprogression, 
postprogression and death) extrapolating 
beyond the 5-year end point of the ICON7 trial 
for bevacizumab in advanced ovarian cancer. 
The study followed on the NICE decision not to 
recommend bevacizumab (a Roche product) 
for advanced ovarian cancer which was not 
based on the unlicensed  lower dosage of the 
drug despite being used in the NHS and the 
ICON7 trial. The analysis, given NICE 
willingness-to-pay thresholds, was to consider 
if the lower dose was cost effective versus 
chemotherapy alone. The base-case analysis 
demonstrated that in none of the scenarios 
was bevacizumab cost-effective at the NICE 
conventional willingness-to-pay thresholds. 
Price reductions of 46% and 67% would be 
required to meet NICE thresholds. In a long-
term scenario price reductions would be 21% 
and 45%. 
Claims presented are 
non-evaluable. While 
the authors 
recommend future 
research no 
recommendation for  
protocols to support 
claims assessment to 
meet required 
standards of normal 
science. 
Altawalbeh 
et al 23 
Older adults 
with persistent 
cancer 
University 
of 
Pittsburgh 
School of 
Pharmacy 
Markov model to estimate incremental costs 
and quality-adjusted life expectancy associated 
with inhaled corticosteroid treatment (ICS) 
with long-acting beta agonists (LABA) 
comparted to ICS with leukotriene receptor 
agonists (LTRA) in older adults with persistent 
asthma. Simulated cohort of persons 65 years 
of age or older ICS+LABA vs. ICS+LTRA. Model 
transition on one-month cycles through 5 
clinical health states followed over 20 years. 
Five health states: healthy without any 
exacerbation, post-asthma exacerbation, post-
cardiovascular  (CV) exacerbation, post 
asthma/CV exacerbation and death. EQ-5D 
utilities from literature or for younger adults 
with asthma. Results: ICS-LABA costs $5,823 
more than ICS + LTRA while gaining 0.03 QALYs 
or $209,090 per QALY. ICS + LABA not 
recommended in this group. 
Claims presented are 
non-evaluable. While 
the authors 
recommend future 
research no 
recommendation for  
protocols to support 
claims assessment to 
meet required 
standards of normal 
science. 
de Boer et 
al24  
Quadrivalent 
vs. trivalent 
influenza 
vaccine  
Sanofi 
Pasteur 
Dynamic transition model to estimate age-
stratified numbers of symptomatic influenza 
cases under quadrivalent vaccine (QIV – 
sponsor’s product) and trivalent (TIV) 
Claims presented are 
non-evaluable and do 
not meet required 
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strategies. Model to estimate impact of QIV 
over TIV in clinical outcomes, costs and health 
effects. Over a 20 year timeframe replacing TIV 
with QIV projected to reduce influenza B cases 
by 27.2% (16.0 million), prevent 137,000 
hospitalizations  and 16,100 deaths, with a 
gain of 212,000 QALYs. ICER projected as 
$27,411/QALY.  
standards of normal 
science. 
Allen R et al25 Chronic 
immune 
thrombocytope
nia 
Glaxo 
Smith Kline 
Markov cohort model comparing response 
after initial treatment with either eltrombopag 
(sponsor’s product) or romiplotsin in 
treatment of chronic immune 
thrombocytopenia. Patients modeled to 
receive a sequence of treatments, time spent 
in each of six health states in each treatment 
arm and lifetime long-term outcomes. 
Modeled results claimed eltrombopag 
dominated romiplostim in both 
splenectomised and nonsplenectomized 
patients. In UK treatment practice there was a 
claimed 99% and 92% chance of eltrombopag 
being cost-effective respectively at the NICE 
willingness to pay threshold of £20,000.  
Claims presented are 
non-evaluable and do 
not meet required 
standards of normal 
science. 
Moran et al26 Screening for 
atrial fibrillation 
No funding  A 25 year Markov model to simulate costs and 
clinical outcomes with and without screening 
for atrial fibrillation in Ireland in persons 65 
years of Age and over in primary care. 
Assuming those detected through screening 
have a comparable stroke risk profile to those 
detected in routine practice, the model 
claimed ICER €23,004/QALY compared to 
routine care.  
Claims presented are 
non-evaluable and do 
not meet required 
standards of normal 
science. 
Bohensky et 
al27 
BRAF wild-type 
melanoma 
None 
stated but  
two of the 
five 
authors are 
employees 
of Bristol-
Myers 
Squibb 
(BMS) in 
Australia  
A state-transition Markov model simulated 
over a 10 year time horizon the to project the 
cost-effectiveness of nivolumab (a BMS 
product approved by PBAC in Australia May 
2016) versus Ipilimumab for previously 
untreated patients with BRAF-advanced 
melanoma. Outcomes modeled were 
progression free survival and and overall 
survival. Quality of life data were from the 
nivolumab trial. Over 10 years nivolumab 
compared to ipilimumab yielded 1,58 life-years 
and 1.30 QALYS per person at a net cost of 
US$39,039 per person. ICER US$25,101 per 
year of life saved and $30,475 per QALY saved. 
Nivolumab was claimed to be cost-effective at 
a willingness to pay threshold of US$35,000. 
Claims presented are 
non-evaluable and do 
not meet required 
standards of normal 
science. 
 
 
 
 
Table 2: Imaginary Worlds: Systematic Reviews of Modeled Economic Evaluation Studies  
Value in Health January 2016 to December 2016 
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Paper (author) Systematic 
Review Focus 
Sponsor (if 
any) 
Modeling Technique and Claims Status Claims Assessment and 
Credibility 
Brilleman et al28 Treatment non-
adherence and 
impact on 
economic 
evaluations 
alongside clinical 
trials 
National 
Institute for 
Health 
Research (UK) 
To review economic evaluations 
alongside clinical trials from the 
perspective of how lack of adherence is 
accommodated and interpreted. 
Adherence, defined as the degree of 
correspondence between a trial 
participants intended and actual 
treatment, was reviewed in 96 eligible 
trials. None of the studies used 
statistical methods to adjust for non-
adherence in the economic evaluation. 
Lack of  standard practice for allocating 
intervention costs to patients on basis of 
degree of adherence. Reporting was not 
comprehensive with the potential for 
biased cost-effectiveness results in 
nontrivial proportion of studies.    
In recommending 
standards for reporting 
and accommodation 
adherence (a clearer 
distinction needs to be 
drawn between 
adherence and 
persistence) behavior 
the review also points 
to a need (unfulfilled) 
for addressing the issue 
in models developed to 
support evaluable and 
replicable claims. 
Nunes et al29 Cost-
effectiveness of 
long-term 
mechanical 
circulatory 
support 
Alberta 
Heritage 
Foundation 
Systematic review of 11 studies 
analyzing cost or cost-effectiveness of 
mechanical circulatory support in end-
stage heart failure. Standard of care 
medical management. Concluded that 
mechanical circulatory support in a 
Canadian environment not cost 
effective. Nevertheless, widespread 
adoption.  
No consideration of 
modeled credible, 
evaluable and 
replicable claims. No 
recommendation for 
meeting required 
standards of normal 
science. 
Kirsch30  Multicomponent 
disease 
management 
models with 
Markov models 
None Systematic review of 16 studies of 
disease management studies utilizing 
variable timeline Markov framework. 
Quality of models and individual study 
characteristics assessed for relevance 
and credibility. Major limitations noted 
included bad reporting practice, 
variation in selection of input 
parameters, number of Markov states 
modeled and time horizons. No 
consensus in outcomes modeled.   
No consideration of 
modeled credible, 
evaluable and 
replicable claims. No 
recommendation for 
meeting required 
standards of normal 
science. 
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